ImmunityBio (IBRX) Other Non Operating Income (2015 - 2026)
ImmunityBio (IBRX) reported Other Non Operating Income of -$236.6 million for Q1 2026, down 455.69% year-over-year from $66.5 million in Q1 2025, and down 16801.79% quarter-over-quarter from -$1.4 million in Q4 2025.
ImmunityBio (IBRX) Other Non Operating Income (2015 - 2026) Analysis & Trends
ImmunityBio (IBRX) has 12 years of Other Non Operating Income data on file, last reported at -$236.6 million in Q1 2026.
- Other Non Operating Income for Q1 2026 came in at -$236.6 million, down 455.69% year-over-year; the trailing twelve-month figure through Mar 2026 was -$238.0 million (down 496.93% YoY), and the FY2025 annual result was $6.4 million, up 42753.33% from the prior year.
- Other Non Operating Income eased to -$236.6 million in Q1 2026 per IBRX's latest filing, from -$1.4 million in the prior quarter.
- Over five years, Other Non Operating Income peaked at $21.2 million in Q2 2024 and troughed at -$236.6 million in Q1 2026.
- A 5-year average of -$19.8 million and a median of -$153000.0 in 2023 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2024 and 2025: Other Non Operating Income surged 75792.86% in 2024, then tumbled 212810.0% in 2025.
- A 5-year view of Other Non Operating Income shows it stood at -$923000.0 in 2022, then jumped by 333.15% to $2.2 million in 2023, then sank by 1033.97% to -$20.1 million in 2024, then surged by 93.03% to -$1.4 million in 2025, then tumbled by 16801.79% to -$236.6 million in 2026.
- Business Quant data shows IBRX's Other Non Operating Income at -$236.6 million in Q1 2026, -$1.4 million in Q4 2025, and $289000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | ImmunityBio | 7.55 Bn | 7.17 Bn | 43.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -236.63 Mn |
| Dec 31, 2025 | -1.40 Mn |
| Sep 30, 2025 | 289,000.00 |
| Jun 30, 2025 | -278,000.00 |
| Mar 31, 2025 | -42.58 Mn |
| Dec 31, 2024 | -20.10 Mn |
| Sep 30, 2024 | 1.61 Mn |
| Jun 30, 2024 | 21.19 Mn |
| Mar 31, 2024 | -20,000.00 |
| Dec 31, 2023 | 2.15 Mn |
| Jun 30, 2023 | -28,000.00 |
| Mar 31, 2023 | -1.08 Mn |
| Dec 31, 2022 | -923,000.00 |
| Mar 31, 2022 | -4,000.00 |
| Dec 31, 2021 | -252,000.00 |
| Sep 30, 2021 | -38,000.00 |
| Jun 30, 2021 | 277,000.00 |
| Mar 31, 2021 | 13,000.00 |
| Dec 31, 2020 | 217,000.00 |
| Sep 30, 2020 | 84,000.00 |